Stephens Inc. AR Makes New $638,000 Investment in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Stephens Inc. AR bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,914 shares of the medical equipment provider's stock, valued at approximately $638,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Deroy & Devereaux Private Investment Counsel Inc. raised its stake in Zimmer Biomet by 0.7% in the third quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 210,312 shares of the medical equipment provider's stock valued at $22,703,000 after buying an additional 1,453 shares during the period. United Asset Strategies Inc. raised its stake in Zimmer Biomet by 2.5% in the 3rd quarter. United Asset Strategies Inc. now owns 15,564 shares of the medical equipment provider's stock valued at $1,680,000 after acquiring an additional 387 shares during the period. Financial Advocates Investment Management boosted its position in Zimmer Biomet by 3.5% during the third quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider's stock worth $330,000 after purchasing an additional 103 shares during the period. Pinnacle Associates Ltd. increased its holdings in shares of Zimmer Biomet by 12.3% in the third quarter. Pinnacle Associates Ltd. now owns 2,298 shares of the medical equipment provider's stock valued at $248,000 after purchasing an additional 252 shares during the last quarter. Finally, First Trust Direct Indexing L.P. raised its position in shares of Zimmer Biomet by 13.7% in the third quarter. First Trust Direct Indexing L.P. now owns 7,836 shares of the medical equipment provider's stock valued at $846,000 after purchasing an additional 943 shares during the period. Institutional investors own 88.89% of the company's stock.

Zimmer Biomet Stock Down 1.3 %

NYSE:ZBH traded down $1.48 during mid-day trading on Thursday, reaching $108.69. The stock had a trading volume of 1,430,739 shares, compared to its average volume of 1,492,484. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The stock's 50 day simple moving average is $106.64 and its two-hundred day simple moving average is $110.58. Zimmer Biomet Holdings, Inc. has a 1-year low of $101.47 and a 1-year high of $133.90. The company has a market capitalization of $21.64 billion, a price-to-earnings ratio of 20.71, a price-to-earnings-growth ratio of 1.99 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting the consensus estimate of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter in the prior year, the firm earned $1.65 EPS. The firm's quarterly revenue was up 4.1% on a year-over-year basis. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Shareholders of record on Monday, September 30th were given a $0.24 dividend. The ex-dividend date of this dividend was Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.88%. Zimmer Biomet's dividend payout ratio (DPR) is presently 18.25%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Royal Bank of Canada upped their price objective on Zimmer Biomet from $120.00 to $125.00 and gave the company an "outperform" rating in a report on Monday. Truist Financial increased their target price on shares of Zimmer Biomet from $112.00 to $117.00 and gave the stock a "hold" rating in a report on Friday, November 1st. Citigroup dropped their price target on shares of Zimmer Biomet from $134.00 to $120.00 and set a "neutral" rating for the company in a research note on Wednesday, July 10th. Wolfe Research assumed coverage on shares of Zimmer Biomet in a research report on Tuesday, September 10th. They set a "peer perform" rating on the stock. Finally, Robert W. Baird decreased their target price on Zimmer Biomet from $155.00 to $145.00 and set an "outperform" rating for the company in a research report on Thursday, August 8th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $124.11.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.